✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Tartaric acid is an investigational drug.
There have been 10 clinical trials for Tartaric acid. The most recent clinical trial was a Phase 2 trial, which was initiated on January 3rd 2020.
The most common disease conditions in clinical trials are Hodgkin Disease, Atrial Fibrillation, and Hyperuricemia. The leading clinical trial sponsors are Boehringer Ingelheim, Mirati Therapeutics Inc., and Shiraz University of Medical Sciences.
There are six hundred and forty-seven US patents protecting this investigational drug and nineteen international patents.
Recent Clinical Trials for Tartaric acid
|Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus||Hospital Espanhol||Phase 2|
|Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus||SENAI CIMATEC||Phase 2|
|A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers||Hamilton Health Sciences Corporation||Phase 4|
Top disease conditions for Tartaric acid
Top clinical trial sponsors for Tartaric acid
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tartaric acid||See Plans and Pricing||Method of diagnosing and treating cancer using B-catenin splice variants||The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)||See Plans and Pricing|
|Tartaric acid||See Plans and Pricing||Use of inhibitors of Bruton'S tyrosine kinase (Btk)||Pharmacyclics LLC (Sunnyvale, CA)||See Plans and Pricing|
|Tartaric acid||See Plans and Pricing||Neprilysin inhibitors||THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Tartaric acid||World Intellectual Property Organization (WIPO)||WO2013170005||2032-05-11||See Plans and Pricing|
|Tartaric acid||World Intellectual Property Organization (WIPO)||WO2016085784||2034-11-26||See Plans and Pricing|
|Tartaric acid||European Patent Office||EP3197455||2034-09-28||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|